STEPHEN A. SHERWIN, M.D. - Corporate Board Profile

BIOGEN INC.

Filing Date	Source Excerpt
2014-04-30	Stephen A. Sherwin, M.D. Age: 65 Director since: 2010 Committee Memberships: Corporate Governance, Science and Technology (Chair)
2015-04-30	Stephen A. Sherwin, M.D. Age: 66 Committee Memberships: Finance, Risk, Science and Technology Dr. Sherwin has served as one of our directors since 2010.
2016-04-15	Dr. Sherwin, 67, has served as one of our directors since 2010. Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company's merger with BioSante Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., most recently as Vice President, Clinical Research. Dr. Sherwin is board certified in internal medicine and medical oncology. Dr. Sherwin has extensive knowledge of the life sciences industry and brings more than 30 years of experience in senior leadership positions at large and small publicly traded life sciences companies to our Board of Directors. Biogen Committee Memberships: Finance, Risk, Science and Technology. 2015 Director Compensation: $403,508.
2017-04-26	Dr. Sherwin, 68, has served as one of our directors since 2010. Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. Biogen Committee Memberships: Finance, Risk, Science and Technology. 2016 Director Compensation: $427,420.
2018-04-27	Dr. Sherwin, 69, has served as one of our directors since 2010. Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. (now Ani Pharmaceuticals, Inc.) in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is a member of the Boards of Directors of Aduro Biotech, Inc. and Neurocrine Biosciences, Inc., both of which are clinical-stage life sciences companies. Dr. Sherwin has extensive knowledge of the life sciences industry and brings more than 30 years of experience in senior leadership positions at large and small publicly traded life sciences companies to our Board of Directors. Biogen Committee Memberships: Finance, Risk, Science and Technology. 2017 Director Compensation: $418,979.
2019-04-30	Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital.
2020-04-20	Dr. Sherwin currently divides his time between advisory work in the life sciences industry... Biogen Board Committee: Audit... 2019 Director Compensation: Stephen A. Sherwin total $411,893.
2021-04-23	Dr. Sherwin is Clinical Professor of Medicine at University of California, San Francisco... Biogen Board Committee: Audit... 2020 Director Compensation: Stephen A. Sherwin total $409,314.
2022-04-29	Dr. Sherwin currently divides his time between advisory work in the life sciences industry... Biogen Board Committee: Audit... 2021 Director Compensation: Stephen A. Sherwin Fees Earned or Paid in Cash $140,000, Stock Awards $270,413, All Other Compensation $50,000, Total $460,413.
2023-04-28	Stephen A. Sherwin, M.D. Director Since: 2010 Age: 74 Biogen Board Committee: Audit 2022 Director Compensation Table: Stephen A. Sherwin Fees Earned or Paid in Cash: $140,000 Stock Awards: $270,246 All Other Compensation: $25,000 Total: $435,246

NEUROCRINE BIOSCIENCES INC

Filing Date	Source Excerpt
2016-05-02	The members of the Audit Committee are Corinne H. Nevinny, Richard F. Pops and Stephen A. Sherwin, M.D. ... The Company 27s Compensation Committee consists of directors Richard F. Pops, George J. Morrow, and Joseph Mollica, Ph.D. ... The Company has a Nominating/Corporate Governance Committee currently comprised Stephen A. Sherwin, M.D., Joseph A. Mollica, Ph.D. and Alfred W. Sandrock, Jr. M.D., Ph.D., all of whom are 3independent directors 4 as defined by Nasdaq Stock Market Rule9605(a)(2). ... 2015 Director Compensation ... Stephen A. Sherwin, M.D. ... $62,000 Fees Earned or Paid in Cash ... $702,185 Option Awards ... $764,185 Total
2017-04-21	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. He is a member of the Audit Committee and the Nominating/Corporate Governance Committee. Director Compensation Table shows total compensation of $475,325 for 2016.
2018-04-04	The continued service of Stephen A. Sherwin, M.D. on the Companys Board of Directors is based on his experience and credentials in the biotechnology industry as the former Chief Executive Officer of Cell Genesys, Inc., the former chairman and co-founder of Abgenix, Inc., the chairman and co-founder of Ceregene, Inc., and his positions at Genentech, Inc. and the National Cancer Institute. Dr. Sherwin currently serves on the Board of Directors of Aduro Biotech and Biogen. He is a Venture Partner with Third Rock Ventures and a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. The Companys Audit Committee is comprised entirely of directors who meet the independence requirements set forth in Nasdaq Stock Market Rule 5605(c)(2)(A). The members of the Audit Committee are Corinne H. Nevinny, Richard F. Pops and Stephen A. Sherwin, M.D. The Companys Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Alfred W. Sandrock, Jr. M.D., Ph.D. The following table sets forth the compensation paid by the Company for the fiscal year ended December 31, 2017 to the directors of the Company named below: Stephen A. Sherwin, M.D.: Fees Earned or Paid in Cash $71,000, Option Awards $442,950, Total $513,950.
2019-04-17	The members of the Audit Committee are Richard F. Pops, George J. Morrow and Stephen A. Sherwin, M.D. The Company 2018 compensation for the Company 2018 to the directors of the Company named below: Stephen A. Sherwin, M.D. 77,333 655,250 732,583
2020-04-09	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. ... Dr. Sherwin currently serves on the Board of Directors of Aduro Biotech, Biogen and Neon Therapeutics. ... Dr. Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School.
2021-04-09	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. The members of the Audit Committee for 2020 were Richard F. Pops, Shalini Sharp and Stephen A. Sherwin, M.D. The Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., George J. Morrow and Leslie V. Norwalk. For 2020, directors who are not employees of the Company earned a $55,000 annual cash retainer. Each other director who was a member of the Audit Committee earned an additional annual cash retainer of $12,000, and each other director who was a member of the Nominating/Corporate Governance Committee earned an additional annual cash retainer of $5,000. Additionally, for 2020, each non-employee director received a grant of a nonstatutory stock option to purchase 6,018 shares of the Companys common stock, representing an approximate value of $400,000 on the date of the 2020 Annual Meeting of Stockholders. The following table sets forth the compensation earned for the fiscal year ended December 31, 2020 by the directors of the Company named below: Stephen A. Sherwin, M.D. Fees Earned or Paid in Cash $87,867 Option Awards $400,030 Total $487,897.
2022-04-07	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. ... The members of the Audit Committee for 2021 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. The Company’s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, with Ms. Norwalk serving as the Nominating/Corporate Governance Committee Chair. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2021 by the directors of the Company named below: Stephen A. Sherwin, M.D. $88,036 fees earned in cash and $400,003 option awards totaling $488,039.
2023-04-05	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. Dr. Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at the Zuckerberg San Francisco General Hospital. Dr. Sherwin currently serves on the Board of Directors of Biogen and the BioPlus Special Purpose Acquisition Corporation. He is an Advisory Partner with Third Rock Ventures and a member of the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy. Previously Dr. Sherwin was Chairman and Chief Executive Officer of Cell Genesys, a cancer immunotherapy company, from 1990 until the company’s merger in 2009 with BioSante Pharmaceuticals (now ANI Pharmaceuticals). He was also a Co-founder and Chairman of Abgenix, an antibody company which was acquired by Amgen in 2006, and co-founder and chairman of Ceregene, a gene therapy company which was acquired by Sangamo Biosciences in 2013. From 1983 to 1990, Dr. Sherwin held various positions in clinical research at Genentech, most recently that of Vice President. Prior to 1983, he was on the staff of the National Cancer Institute. In addition, Dr. Sherwin previously served on the board of directors of Aduro Biotech, Neon Therapeutics, as well as the Biotechnology Industry Organization from 2001 to 2014 and as its chairman from 2009 to 2011, and was a member of the President’s Council of Advisors in Science and Technology (PCAST) Working Group on Drug Development from 2011 to 2013. Dr. Sherwin holds a B.A. in biology summa cum laude from Yale University and an M.D. from Harvard Medical School, is board-certified in internal medicine and medical oncology, and is a Fellow of the American College of Physicians. The Company’s Nominating/Corporate Governance Committee consists of directors Stephen A. Sherwin, M.D., Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, with Ms. Norwalk serving as the Nominating/Corporate Governance Committee Chair.
2024-04-10	Stephen A. Sherwin, M.D. has served on the Board of Directors since April 1999. ... Dr. Sherwin currently serves on the Board of Directors of Biogen Inc., a publicly traded company. ... The Company’s Audit Committee is comprised entirely of directors who meet the independence requirements set forth in Nasdaq Stock Market Rule 5605(c)(2)(A). ... The members of the Audit Committee for 2023 were Richard F. Pops, Shalini Sharp, and Stephen A. Sherwin, M.D., with Ms. Sharp serving as the Audit Committee Chair. ... During 2023, the Company’s Nominating / Corporate Governance Committee consisted of directors Johanna Mercier, George J. Morrow, and Leslie V. Norwalk, and Stephen A. Sherwin, M.D., with Ms. Norwalk serving as the Nominating / Corporate Governance Committee Chair. ... In January 2024, the Board formed the Science and Medical Technology Committee, which provides oversight of significant scientific judgments relating to the Company’s research and development, including clinical development, activities, portfolio, and potential business development transactions. The Science and Medical Technology Committee consists of directors Stephen A. Sherwin, M.D., William H. Rastetter, Ph.D., Gary A. Lyons, and Richard F. Pops, with Dr. Sherwin serving as the Science and Medical Technology Committee Chair. ... For fiscal 2023, directors who are not employees of the Company earned a $60,000 annual cash retainer. ... For fiscal 2023, on the date of the 2023 Annual Meeting of Stockholders, each continuing non-employee director received an annual equity award with an approximate grant date value of $400,000. ... The following table sets forth the compensation earned for the fiscal year ended December 31, 2023 by the directors of the Company named below: ... Stephen A. Sherwin, M.D. $79,500 cash fees, $400,039 stock awards, total $479,539.